following the discovery of ALK translocations in a fraction of non-small-cell lung cancers and in other solid tumours. In cancers, all translocations involving ALK produce fusion proteins with ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

An isogenic cell line was created to model cancer ... ALK. We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...